Drug Discovery (758 k
http://www.kubinyi.de/dd-01.pdf
Serendipity and Rational Design (374 k
http://www.kubinyi.de/dd-02.pdf
Chemogenomics (1,453 k
http://www.kubinyi.de/dd-03.pdf
Ligand-Receptor Interactions (647 k
http://www.kubinyi.de/dd-04.pdf
Hydrogen Bonds and Biological Activities (359 k
http://www.kubinyi.de/dd-05.pdf
Chemical Similarity and Biological Activities (686 k
http://www.kubinyi.de/dd-06.pdf
Drug Metabolism (501 k
http://www.kubinyi.de/dd-07.pdf
Peptidomimetics and Prodrugs (294 k
http://www.kubinyi.de/dd-08.pdf
Combinatorial Chemistry Technology (147 k
http://www.kubinyi.de/dd-09.pdf
Combinatorial Chemistry in Drug Research (215 k
http://www.kubinyi.de/dd-10.pdf
QSAR Parameters (284 k
http://www.kubinyi.de/dd-11.pdf
QSAR - Hansch and Free Wilson Analyses (153 k
http://www.kubinyi.de/dd-12.pdf
Variable Selection and Model Validation (935 k
http://www.kubinyi.de/dd-13.pdf
Nonlinear QSAR and 3D QSAR (173 k
http://www.kubinyi.de/dd-14.pdf
QSAR Examples (138 k
http://www.kubinyi.de/dd-15.pdf
Structure-Based Ligand Design (782 k
http://www.kubinyi.de/dd-16.pdf
Computer-Aided Ligand Design (850 k
http://www.kubinyi.de/dd-17.pdf
Pharmacophore Analyses (486 k
http://www.kubinyi.de/dd-18.pdf
Virtual Screening (299 k
http://www.kubinyi.de/dd-19.pdf
Combinatorial and Fragment-Based Ligand Design (945 k
http://www.kubinyi.de/dd-20.pdf
Serine Proteases and their Inhibitors (371 k
http://www.kubinyi.de/dd-21.pdf
Thrombin Inhibitor Design (332 k
http://www.kubinyi.de/dd-22.pdf
Problems in Drug Design (1,043 k
http://www.kubinyi.de/dd-23.pdf
In Search for New Leads
http://www.kubinyi.de/paris-07-05.pdf
From Leads to Drugs
http://www.kubinyi.de/wien-06-05.pdf
Validation and Predictivity of QSAR Models
http://www.kubinyi.de/istanbul-2004-lecture.pdf 上一篇：天然产物化学药物合成 下一篇：软胶囊剂各工序质量控制
